Protocol Details
Natural History of Depression, Bipolar Disorder and Suicide Risk
This study is currently recruiting participants.
Summary
Number |
001874-M |
Sponsoring Institute |
National Institute of Mental Health (NIMH) |
Recruitment Detail |
Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 120 Years |
Referral Letter Required |
No |
Population Exclusion(s) |
Adults who are or may become unable to consent;
Children;
Fetuses;
Neonates;
Non-English Speaking;
Pregnant Women |
Keywords |
Neurobiology;
Suicide;
Major Depressive Disorder;
Bipolar Disorder;
Biomarkers;
Suicide Risk;
Treatment Resistant Depression |
Recruitment Keyword(s) |
None |
Condition(s) |
Behavioral Symptoms;
suicide;
Self-Injurious Behavior;
Sensory System Agents;
Analgesics;
Peripheral Nervous System Agents;
Physiological Effects of Drugs;
Anesthetics, Dissociative;
Anesthetics, General;
Anesthetics;
Central Nervous System Depressants;
Excitatory Amino Acid Antagonists;
Excitatory Amino Acid Agents;
Neurotransmitter Agents;
Molecular Mechanisms of Pharmacological Action;
Ketamine;
Depression, Unipolar;
Depressive Symptoms;
Treatment Resistant Depression;
Major Depressive Disorder;
Depression, Bipolar |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
None |
Supporting Site |
National Institute of Mental Health |
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide.
People 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254.
This study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time.
Participants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation.
Eligibility
INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-Signed consent for Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers
-Age 18 years or older
-Able to provide informed consent
-Able to read and write English
EXCLUSION CRITERIA:
-Unstable medical conditions in the opinion of the investigator that would preclude participation in outpatient or inpatient treatment.
-Pregnancy
-Participation in the Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers, as a healthy volunteer.
-Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to consent and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to enrolling in the study. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT06462196